XML 43 R33.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017
Revenues: |  |  |  |
Total | $ 23,562 | $ 11,812 | $ 57,615 | $ 23,490
Recognition of Upfront Fee [Member] |  |  |  |
Revenues: |  |  |  |
Total | 23,538 | 11,759 | 57,378 | 23,042
Kite Pharma, Inc. ("Kite") [Member] |  |  |  |
Revenues: |  |  |  |
Total | 9,028 |  | 16,544 |
Kite Pharma, Inc. ("Kite") [Member] | Recognition of Upfront Fee [Member] |  |  |  |
Revenues: |  |  |  |
Total | 6,296 |  | 12,249 |
Kite Pharma, Inc. ("Kite") [Member] | Research Services [Member] |  |  |  |
Revenues: |  |  |  |
Total | 2,732 |  | 4,295 |
Pfizer Collaboration for SB-525 | Recognition of Upfront Fee [Member] |  |  |  |
Revenues: |  |  |  |
Total | 10,421 | 6,624 | 26,262 | 10,384
Bioverativ Inc [Member] |  |  |  |
Revenues: |  |  |  |
Total | 2,240 | 3,401 | 11,139 | 9,062
Bioverativ Inc [Member] | Recognition of Upfront Fee [Member] |  |  |  |
Revenues: |  |  |  |
Total | 1,094 | 442 | 3,432 | 1,326
Bioverativ Inc [Member] | Research Services [Member] |  |  |  |
Revenues: |  |  |  |
Total | $ 1,146 | 2,959 | $ 7,707 | 7,736
Shire AG [Member] |  |  |  |
Revenues: |  |  |  |
Total |  | 1,172 |  | 2,449
Shire AG [Member] | Recognition of Upfront Fee [Member] |  |  |  |
Revenues: |  |  |  |
Total |  | 1,166 |  | 2,333
Shire AG [Member] | Research Services [Member] |  |  |  |
Revenues: |  |  |  |
Total |  | $ 6 |  | $ 116

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BioverativIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_ShireAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |